9359 View: Overview Glossary  HistCite Guide
Author(s)Wahle KWJ; Heys SD; Rotondo D
TitleConjugated linoleic acids: are they beneficial or detrimental to health?
SourcePROGRESS IN LIPID RESEARCH 43 (6): 553-587
Date2004 NOV
TypeJournal : Review
LCR52   NCR: 177   LCS: 0   GCS: 0
Comment 
AddressRobert Gordon Univ, Sch Life Sci, Aberdeen AB25 1GH, Scotland.
Univ Aberdeen, Sch Med, Dept Surg & Nutrit Oncol, Aberdeen AB25, Scotland.
Univ Strathclyde, Dept Immunol, Glasgow G4 0NR, Lanark, Scotland.
ReprintWahle, KWJ, Robert Gordon Univ, Sch Life Sci, Aberdeen AB25 1GH,
Scotland.
E-mailk.wahle-l@rgu.ac.uk
AbstractConjugated linoleic acids (CLAs) comprise a family of positional and geometric isomers of linoleic acid (18:2n - 6; LA) that are formed by biohydrogenation and oxidation processes in nature. The major dietary sources of these unusual fatty acids are foods derived from ruminant animals, in particular dairy products. The main form of CLA, cis-9, trans-11-18:2, can be produced directly by bacterial hydrogenation in the rumen or by delta-9 desaturation of the co-product vaccenic acid (trans-11-18:1) in most mammalian tissues including man. The second most abundant isomer of CLA is the trans-10, cis-12-18:2 form. Initially identified in grilled beef as a potential anti-carcinogen a surprising number of health benefits have subsequently been attributed to CLA mixtures and more recently to the main individual isoforms. It is also clear from recent studies that the two main isoforms can have different effects on metabolism and cell functions and can act through different cell signalling pathways. The majority of studies on body compositional effects (i.e. fat loss, lean gain), on cancer and cardiovascular disease attenuation, on insulin sensitivity and diabetes and on immune function have been conducted with a variety of animal models. Observations clearly emphasise that differences exist between mammalian species in their response to CLAs with mice being the most sensitive. Recent studies indicate that some but not all of the effects observed in animals also pertain to human volunteers. Reports of detrimental effects of CLA intake appear to be largely in mice and due mainly to the trans-10, cis-12 isomer. Suggestions of possible deleterious effects in man due to an increase in oxidative lipid products (isoprostanes) with trans-10, cis-12 CLA ingestion require substantiation. Unresponsiveness to antioxidants of these non-enzymatic oxidation products casts some doubt on their physiological relevance. Recent reports, albeit in the minority, that CLAs, particularly the trans-10, cis-12 isomer, can elicit pro-carcinogenic effects in animal models of colon and prostate cancer and can increase prostaglandin production in cells also warrant further investigation and critical evaluation in relation to the many published anticancer and anti-prostaglandin effects of CLAs. (C) 2004 Elsevier Ltd. All rights reserved.
CR 1997, FOOD NUTR PREVENTION
ADLOF R, 2003, ADV CONJUGATED LINOL, V2, P37
AKAHOSHI A, 2002, BIOSCI BIOTECH BIOCH, V66, P916
AKAHOSHI A, 2004, LIPIDS, V39, P25
ALBERS R, 2003, EUR J CLIN NUTR, V57, P595
ARO A, 2000, NUTR CANCER, V38, P151
ATKINSON RL, 1999, ADV CONJUGATED LINOL, V1, P348
AZAIN MJ, 2000, J NUTR, V130, P1548
BALDWIN AS, 2001, J CLIN INVEST, V107, P3
BANNI S, 2003, ADV CONJUGATED LINOL, V2, P267
BARBER MD, 2001, NUTR CANC, V49, P118
BASSAGANYARIERA J, 2001, J NUTR, V131, P2370
BASSAGANYARIERA J, 2003, J NUTR, V133, P3204
BAUMGARD LH, 2002, J DAIRY SCI, V85, P2155
BELURY MA, 1997, NUTR DIS UPDATE, V1, P58
BELURY MA, 1999, ADV CONJUGATED LINOL, V1, P404
BELURY MA, 2002, ANNU REV NUTR, V22, P505
BELURY MA, 2002, J NUTR, V132, P2995
BELURY MA, 2002, NUTR RES, V22, P817
BELURY MA, 2003, ADV CONJUGATED LINOL, V2, P302
BINGHAM SA, 2002, CANCER EPIDEM BIOMAR, V11, P672
BLANKSON H, 2000, J NUTR, V130, P2943
BORGESON CE, 1989, LIPIDS, V24, P290
BRODIE AE, 1999, J NUTR, V129, P602
CESANO A, 1998, ANTICANCER RES, V18, P1429
CHAJES V, 2002, CANCER EPIDEM BIOMAR, V11, P672
CHAJES V, 2003, NUTR CANCER, V45, P17
CHILLIARD Y, 2001, LIVEST PROD SCI, V70, P31
CHO HJ, 2003, AM J PHYSIOL-GASTR L, V284, PG996
CHRISTIE WW, 2003, ADV CONJUGATED LINOL, V2, P1
COHEN LA, 2003, PROSTATE, V54, P169
COOK ME, 2003, ADV CONJUGATED LINOL, V2, P283
CROSBY AJ, 1996, BBA-LIPID LIPID MET, V1303, P187
DAVIDSON J, 2001, PFLUG ARCH EUR J PHY, V442, P526
DEKRUYFF RH, 1993, SEMIN IMMUNOL, V5, P421
DEL PG, 1988, J IMMUNOL, V140, P4193
DELANY JP, 1999, AM PHYSL SOC, PR1172
DELERIVE P, 1999, J BIOL CHEM, V274, P32048
DELERIVE P, 2001, J ENDOCRINOL, V169, P453
DELPRETE G, 1992, ALLERGY, V47, P450
DELPRETE G, 1998, INT REV IMMUNOL, V16, P427
DINARELLO CA, 1997, CYTOKINE GROWTH F R, V8, P253
DINARELLO CA, 1999, J INFECT DIS S2, V179, PS294
DOBSON G, 2003, ADV CONJUGATED LINOL, V2, P13
DURGAM VR, 1997, CANCER LETT, V116, P121
EDER K, 2003, J NUTR, V133, P4083
FARQUHARSON A, 1999, LIPIDS S, V34, PS343
FISHER SM, 1995, SKIN CANC MECH HUMAN, P129
FITE A, 2001, EUR J SURG ONCOL, V27, P798
FITE A, 2004, CARCINOGENESIS
FRITSCHE J, 1999, ADV CONJUGATED LINOL, V1, P378
FRUCHART JC, 1999, CURR OPIN LIPIDOL, V10, P245
GAVINO VC, 2000, J NUTR, V130, P27
GOUA M, 2002, 43 INT C BIOSC LIP G
GOUA M, 2003, 44 INT C BIOSC LIP O
GREENBERG AS, 1992, CANCER RES, V52, P4113
GRIINARI JM, 1999, ADV CONJUGATED LINOL, V1, P180
GRIMBLE RF, 1998, NUTRITION, V14, P634
GULATI SK, 2000, ANIM FEED SCI TECH, V86, P139
HA JH, 2003, J FOOD SCI NUTR, V8, P253
HA YL, 1987, CARCINOGENESIS, V8, P1881
HA YL, 1990, CANCER RES, V50, P1097
HARBIGE LS, 2003, LIPIDS, V38, P323
HEYS SD, UNPUB
HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409
HOUSEKNECHT KL, 1998, BIOCHEM BIOPH RES CO, V244, P678
HOUSEKNECHT KL, 2002, DOMEST ANIM ENDOCRIN, V22, P1
HOWE GR, 1990, J NATL CANCER I, V82, P561
HUBBARD NE, 2000, CANCER LETT, V150, P93
HUNTER DJ, 1996, NEW ENGL J MED, V334, P356
HWANG DH, 1979, PROSTAGLANDINS, V17, P543
IGARASHI M, 2001, BBA-MOL CELL BIOL L, V1530, P162
IP C, 1995, NUTR CANCER, V24, P241
IP C, 2000, CANCER EPIDEM BIOMAR, V9, P689
IP C, 2002, NUTR CANCER, V43, P52
IP MM, 1999, EXP CELL RES, V250, P22
IWAKIRI Y, 2002, PROSTAG LEUKOTR ESS, V67, P435
JIANG CY, 1998, NATURE, V391, P82
KARMALI RA, 1984, J NATL CANCER I, V73, P457
KATAN MB, 1995, ANNU REV NUTR, V15, P473
KAVANAUGH CJ, 1999, NUTR CANCER, V33, P132
KEIM NL, 2003, ADV CONJUGATED LINOL, V2, P316
KELLEY DS, 2001, LIPIDS, V36, P669
KELLEY DS, 2003, LIPIDS, V38, P377
KHAZAAI H, 1997, THESIS ABERDEEN U
KLIEWER SA, 1997, P NATL ACAD SCI USA, V94, P4318
KLINGENBERG M, 1999, BBA-BIOMEMBRANES, V1415, P271
KNEKT P, 1999, ADV CONJUGATED LINOL, V1, P444
KRITCHEVSKY D, 1999, ADV CONJUGATED LINOL, V1, P397
KRITCHEVSKY D, 2002, 1 INT C CONJ LIN AC
KRITCHEVSKY D, 2002, NUTR RES, V22, P1275
LEDOUX M, 2003, SCI ALIMENT, V23, P443
LEE KN, 1994, ATHEROSCLEROSIS, V108, P19
LEHMANN JM, 1995, J BIOL CHEM, V270, P12953
LIEW C, 1995, CARCINOGENESIS, V16, P3037
LU M, 2002, FASEB J, V14, PA721
MA DWL, 2002, J AM OIL CHEM SOC, V79, P755
MAJUMDER B, 2002, FASEB J, V16, P1447
MASSOWELCH PA, 2001, BREAST CANCER RES TR, V68, P211
MASSOWELCH PA, 2004, J NUTR, V134, P299
MCCARTHYBECKETT DO, 2002, RES NURS HEALTH, V25, P49
MCGUIRE MA, 1999, ADV CONJUGATED LINOL, V1, P295
MEDINA EA, 2000, LIPIDS, V35, P783
MILLER A, 2002, ANTICANCER RES, V22, P3879
MINER JL, 2001, OBES RES, V9, P129
MOON EJ, 2003, ONCOL REP, V10, P617
MOYACAMARENA SY, 1999, J LIPID RES, V40, P1426
MUNDAY JS, 1999, BRIT J NUTR, V81, P251
NAKANISHI T, 2003, NEUROSCI LETT, V341, P135
NICOLOSI RJ, 1997, ARTERY, V22, P266
OCHOA JJ, CARCINOGENESIS, V25, P1185
OEETGEN P, 2001, CIRC RES, V89, P380
OGBORN MR, 2003, KIDNEY INT, V64, P1214
OHNUKI K, 2001, LIPIDS, V36, P583
PALUMBO JD, 2002, CANC LETT, V177, P163
PARIZA MW, 1985, CARCINOGENESIS, V6, P591
PARIZA MW, 1988, ANNU REV NUTR, V8, P167
PARIZA MW, 1999, TOXICOL SCI S, V52, P107
PARIZA MW, 2000, P SOC EXP BIOL MED, V223, P8
PARIZA MW, 2003, ADV CONJUGATED LINOL, V2, P251
PARK HS, 2001, BRIT J NUTR, V86, P549
PARK Y, 1999, LIPIDS, V34, P243
PARODI PW, 1997, J NUTR, V127, P1055
PARODI PW, 2003, ADV CONJUGATED LINOL, V2, P101
PARRISH FC, 2003, ADV CONJUGATED LINOL, V2, P189
PETRIK MBH, 2000, J NUTR, V130, P2434
RAHMAN SM, 2001, NUTRITION, V17, P385
RAJAKANGAS J, 2003, J NUTR, V133, P1943
REINER SL, 2001, CURR OPIN IMMUNOL, V13, P351
RICOTE M, 1998, NATURE, V391, P79
RISERUS U, 2001, INT J OBESITY, V25, P1129
ROCHE HM, 2002, DIABETES, V51, P2037
ROTONDO D, 1988, EUR J PHARMACOL, V154, P145
SAEBO A, 2003, ADV CONJUGATED LINOL, V2, P71
SATORY DL, 1999, J NUTR, V129, P92
SCIMECA JA, 1999, ADV CONJUGATED LINOL, V1, P420
SHAO Y, 1995, LIPIDS, V30, P1035
SHAO Y, 1997, NUTR CANCER, V28, P63
SISK MB, 2001, J NUTR, V131, P1668
SMEDMAN A, 2001, LIPIDS, V36, P773
SNEDDON AA, 2003, ATHEROSCLEROSIS, V171, P57
SONG HJ, 2001, AJI ICBL BERG NORW S
SONG HJ, 2002, CHEM PHYS LIPIDS, V118, P109
SONG HJ, 2004, EUR J CLIN NUTR
SONG HJ, NUTR CANC, V49, P100
STANTON C, 2003, ADV CONJUGATED LINOL, V2, P123
SUFFREDINI AF, 1999, J CLIN IMMUNOL, V19, P203
SUGANO M, 1998, LIPIDS, V33, P521
TALAMINI R, 1984, BRIT J CANCER, V49, P723
THOM E, 2001, J INT MED RES, V29, P392
TOOMEY S, 2003, BIOCHEM SOC T 5, V31, P1075
TORRESDUARTE AP, 2003, BBA-MOL CELL RES, V1640, P69
TSUBOYAMAKASAOKA N, 2000, DIABETES, V49, P1534
TURPEINEN AM, 2002, AM J CLIN NUTR, V76, P504
URADE Y, 1989, J IMMUNOL, V143, P2982
URQUHART P, 2002, BBA-MOL CELL BIOL L, V1580, P150
VOORRIPS LE, 2002, AM J CLIN NUTR, V76, P873
WAHLE KW, 1999, CURR OPIN CLIN NUTR, V2, P109
WAHLE KWJ, 1993, EUR J CLIN NUTR, V47, P828
WAHLE KWJ, 1994, ROYAL COLL GEN PRACT, P541
WAHLE KWJ, 2002, PROSTAG LEUKOTR ESS, V67, P183
WAHLE KWJ, 2003, P NUTR SOC, V62, P349
WAHLE KWJ, UNPUB
WARREN JM, 2003, LIPIDS, V38, P497
WEST DB, 1998, AM J PHYSIOL-REG I, V275, PR667
WEST DB, 2000, J NUTR, V130, P2471
WHIGHAM LD, 2001, AM J PHYSIOL-REG I, V280, PR908
WIGMORE SJ, 2000, NUTR CANCER, V36, P177
WONG MW, 1997, ANTICANCER RES, V17, P987
YAMASAKI M, 2002, J NUTR SCI VITAMINOL, V48, P505
YAMASAKI M, 2003, NUTRITION, V19, P30
YANG HY, 2003, MUTAGENESIS, V18, P195
YANG MD, 2003, EXP BIOL MED, V228, P51
YU Y, 2002, BIOCHIM BIOPHYS ACTA, V158, P88
ZAMBELL KL, 2000, LIPIDS, V35, P777
ZAMBELL KL, 2001, LIPIDS, V36, P767
ZHANG X, 2002, INT IMMUNOPHARMACOL, V2, P1029